JP2004532266A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532266A5
JP2004532266A5 JP2003500073A JP2003500073A JP2004532266A5 JP 2004532266 A5 JP2004532266 A5 JP 2004532266A5 JP 2003500073 A JP2003500073 A JP 2003500073A JP 2003500073 A JP2003500073 A JP 2003500073A JP 2004532266 A5 JP2004532266 A5 JP 2004532266A5
Authority
JP
Japan
Prior art keywords
methyl
compound according
ylcarbonyl
thiazol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003500073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532266A (ja
Filing date
Publication date
Priority claimed from GBGB0113233.1A external-priority patent/GB0113233D0/en
Application filed filed Critical
Publication of JP2004532266A publication Critical patent/JP2004532266A/ja
Publication of JP2004532266A5 publication Critical patent/JP2004532266A5/ja
Pending legal-status Critical Current

Links

JP2003500073A 2001-05-31 2002-05-29 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体 Pending JP2004532266A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0113233.1A GB0113233D0 (en) 2001-05-31 2001-05-31 Chemical compounds
PCT/EP2002/005885 WO2002096894A1 (en) 2001-05-31 2002-05-29 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases

Publications (2)

Publication Number Publication Date
JP2004532266A JP2004532266A (ja) 2004-10-21
JP2004532266A5 true JP2004532266A5 (enExample) 2005-12-22

Family

ID=9915638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003500073A Pending JP2004532266A (ja) 2001-05-31 2002-05-29 心血管系疾患の治療に有用なチアゾールまたはオキサゾール誘導体

Country Status (21)

Country Link
US (1) US6867225B2 (enExample)
EP (1) EP1392665B1 (enExample)
JP (1) JP2004532266A (enExample)
KR (1) KR20040007633A (enExample)
CN (1) CN1529698A (enExample)
AT (1) ATE377007T1 (enExample)
AU (1) AU2002312954B2 (enExample)
BR (1) BR0210077A (enExample)
CA (1) CA2448103A1 (enExample)
CO (1) CO5540299A2 (enExample)
CZ (1) CZ20033250A3 (enExample)
DE (1) DE60223245T2 (enExample)
ES (1) ES2295352T3 (enExample)
GB (1) GB0113233D0 (enExample)
HU (1) HUP0400056A2 (enExample)
IL (1) IL158818A0 (enExample)
MX (1) MXPA03010584A (enExample)
NO (1) NO20035316D0 (enExample)
PL (1) PL367215A1 (enExample)
WO (1) WO2002096894A1 (enExample)
ZA (1) ZA200308864B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
WO2004022551A1 (ja) 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited フランまたはチオフェン誘導体およびその医薬用途
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
FR2901792A1 (fr) * 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
TW201022221A (en) 2008-12-01 2010-06-16 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivatives containing thiazole ring and pharmaceutical use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2020033919A1 (en) 2018-08-10 2020-02-13 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6207422B1 (en) * 1998-04-17 2001-03-27 The Metrohealth System Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same
US6214620B1 (en) * 1998-09-29 2001-04-10 The Johns Hopkins University Inducible genetic suppression of cellular excitability
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール

Similar Documents

Publication Publication Date Title
JP2004532266A5 (enExample)
JP2004517100A5 (enExample)
JP2007510662A5 (enExample)
JP2005508905A5 (enExample)
JP2005529965A5 (enExample)
JP2004516314A5 (enExample)
JP2004534035A5 (enExample)
JP2011137006A5 (enExample)
JP2011511075A5 (enExample)
JP2008511683A5 (enExample)
JP2005507918A5 (enExample)
JP2006520755A5 (enExample)
JP2009537524A5 (enExample)
NO20053211L (no) Forbindelser for behandling av metabolske forstyrrelser.
JP2003502369A5 (enExample)
JP2010523476A5 (enExample)
JP2004530656A5 (enExample)
JP2007523155A5 (enExample)
JP2005537248A5 (enExample)
CA2500964A1 (en) Cyclohexyl sulphone derivatives as gamma-secretase inhibitors
RU2002115263A (ru) 5-членные N-гетероциклические соединения, обладающие гипогликемической и гиполипидемической активностью
JP2013532726A5 (enExample)
JP2002513793A5 (enExample)
JP2018135343A5 (enExample)
JP2016531126A5 (enExample)